Table of contents
Possible scenarios of the development of antibiotic resistance in patients with urinary tract infection after the COVID-19 pandemic era
An outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the causative pathogen for COVID-19 was reported at the end of December 2019 in Wuhan, Hubei province, China, and by March 2020, it was declared a pandemic COVID-19. In hospital and critical care department settings, the majority of patients with COVID-19 receive broad-spectrum antibiotics for treatment of secondary infection complications. In patients affected by COVID-19, who had a suspected secondary bacterial superinfection, antibiotics including teicoplanin, clarithromycin, doxycycline, azithromycin, tetracyclines, levofloxacin, moxifloxacin, ciprofloxacin, and cephalosporins 3d generation were proposed as an effective treatment. In this editorial, we will consider possible scenarios of the development of antibiotic resistance after the pandemic COVID-19 in patients with urinary tract infection (UTI).
Keywords: COVID-19, antibiotic resistance, urinary tract infection, bacterial superinfection